1094 related articles for article (PubMed ID: 24442885)
1. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
3. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP
Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
5. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
[TBL] [Abstract][Full Text] [Related]
7. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
10. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
12. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Borrirukwisitsak S; Tantayakom P; Katchamart W
Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
[TBL] [Abstract][Full Text] [Related]
18. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
19. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
[TBL] [Abstract][Full Text] [Related]
20. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]